Neurocrine Biosciences to Host R&D Day on December 16

Core Insights - Neurocrine Biosciences, Inc. will hold its 2025 R&D Day on December 16, 2025, at 12:00 p.m. Eastern Time in San Diego [1] - The event will showcase the company's ongoing R&D transformation and its expanding neuroscience pipeline, featuring a discussion with key opinion leader John Krystal, M.D. from Yale University [2] Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [4] - The company has a diverse portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, and endometriosis, along with a robust pipeline of compounds in mid- to late-phase clinical development [4]